Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hypnosis and VR tested to calm leukemia Patients' fears

NCT ID NCT07386392

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares hypnosis, virtual reality, and standard care to see which best reduces anxiety in adults starting chemotherapy for acute myeloid leukemia. About 99 patients will be randomly assigned to one of three groups. The goal is to find a non-drug way to help patients cope with the stress of diagnosis and intensive treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypnosis and virtual reality sessions
What this could lead to
If it works, this could offer simple, drug-free ways to ease severe anxiety during leukemia treatment, improving patient well-being.
What could go wrong
This is a small pilot study (99 people) that hasn't started yet. The effects may be small or not last, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over the age of 18 * Patient diagnosed with acute myeloid leukemia in Western Occitanie * Eligible for first-line induction chemotherapy with anthracycline and cytarabine * Patient able to understand and respond to a self-administered questionnaire * Affiliated with or beneficiary of a social security system * Having signed the research consent form Exclusion Criteria: * Patients diagnosed with acute myeloid leukemia 3 * Patients who were treated in intensive care prior to hospitalization for induction therapy or following induction therapy * Patients with a diagnosed chronic pain-inducing disease (e.g., rheumatoid arthritis), if not stable * Patients with a confirmed diagnosis of psychopathology such as psychosis, depression, or burnout, if not stable * Patients suffering from epilepsy, whether treated or not, or with a history of epilepsy * Patients under guardianship, conservatorship, or legal protection * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IUCT Oncopole

    Toulouse, France, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.